Patents by Inventor Lily Lee

Lily Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic agents and methods of use thereof for the treatment of melanoma
    Patent number: 7405194
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: July 29, 2008
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Methionine aminopeptidase-2 inhibitors and methods of use thereof
    Patent number: 7348307
    Abstract: The present invention provides methods of treating a lymphoma (e.g.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: March 25, 2008
    Assignee: Praecis Pharmaceuticals Incorporated
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS
    Publication number: 20070270425
    Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Application
    Filed: December 12, 2006
    Publication date: November 22, 2007
    Inventors: Guozhang Xu, Lily Lee, Terry Hughes, Steven Wetter, Peter Connolly, Marta Abad, Stuart Emanuel, Prabha Karnachi, Steven Middleton
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Patent number: 7268111
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: September 11, 2007
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft
  • Methionine aminopeptidase-2 inhibitors and methods of use thereof
    Publication number: 20070161570
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of inducing an immunosupressed condition and/or treating chronic allograft vasculopathy in a subject undergoing or who has undergone a transplant, by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.
    Type: Application
    Filed: July 21, 2006
    Publication date: July 12, 2007
    Applicant: Praecis Pharmaceuticals, Inc.
    Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Publication number: 20070117758
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: November 7, 2006
    Publication date: May 24, 2007
    Applicant: Praecis Pharmaceuticals, Inc.
    Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
  • Methionine aminopeptidase-2 inhibitors and methods of use thereof
    Publication number: 20070010452
    Abstract: The present invention provides methods of parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.
    Type: Application
    Filed: May 3, 2006
    Publication date: January 11, 2007
    Applicant: Praecis Pharmaceuticals, Inc.
    Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Patent number: 7157420
    Abstract: The present invention provides methods of treating an autoimmune disorder (e.g., lupus erythematosus, multiple sclerosis, myasthenia gravis, vasculitis and diabetes mellitus) in a subject by administering to the subject a therapeutically effective amount of one or more compounds of the invention.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: January 2, 2007
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Publication number: 20060223758
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: March 24, 2006
    Publication date: October 5, 2006
    Applicant: Praecis Pharmaceuticals, Inc.
    Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
  • Methionine aminopeptidase-2 inhibitors and methods of use thereof
    Patent number: 7105482
    Abstract: The present invention provides methods of treating, parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: September 12, 2006
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Patent number: 7084108
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: August 1, 2006
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Patent number: 7037890
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: May 2, 2006
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Publication number: 20060069028
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: September 27, 2005
    Publication date: March 30, 2006
    Applicant: Praecis Pharmaceuticals, Inc.
    Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Patent number: 6919307
    Abstract: The present invention provides methods of treating a parasitic infection, a lymphoid malignancy or an autoimmune disorder in a subject by administering to the subject a therapeutically effective amount of an angiogenesis inhibitor compound comprising a MetAP-2 inhibitory core coupled to a peptide.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: July 19, 2005
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Publication number: 20050130903
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: October 8, 2004
    Publication date: June 16, 2005
    Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
  • Methionine aminopeptidase-2 inhibitors and methods of use thereof
    Publication number: 20050059585
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: May 2, 2003
    Publication date: March 17, 2005
    Applicant: Praecis Pharmaceuticals Inc.
    Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
  • Substituted phenyl acetamides and their use as protease inhibitors
    Publication number: 20040254166
    Abstract: Phenyl acetamide compounds are described, including compounds of Formula I: 1
    Type: Application
    Filed: April 1, 2004
    Publication date: December 16, 2004
    Inventors: Kevin D. Kreutter, Lily Lee, Tianbao Lu, Venkatraman Mohan, Sharmila Patel, Hui Huang, Guozhang Xu, Mark Fitzgerald
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Publication number: 20030109671
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: May 2, 2002
    Publication date: June 12, 2003
    Applicant: Praecis Pharmaceuticals Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Patent number: 6548477
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Grant
    Filed: November 1, 2000
    Date of Patent: April 15, 2003
    Assignee: Praecis Pharmaceuticals Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens J. Birktoft
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Publication number: 20020193298
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: October 5, 2001
    Publication date: December 19, 2002
    Applicant: Praecis Pharmaceuticals Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft